MK-0616 (Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
Status:
Recruiting
Trial end date:
2029-11-29
Target enrollment:
Participant gender:
Summary
This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of
MK-0616, an oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in
participants with high cardiovascular risk. The primary objective is to evaluate the efficacy
of MK-0616 compared with placebo in increasing the time to the first occurrence of major
adverse cardiovascular events (MACE) including coronary heart disease (CHD) death, ischemic
stroke, myocardial infarction (MI), acute limb ischemia or major amputation, or urgent
arterial revascularization.